Vaginal clindamycin is prescribed in the United States for bacterial vaginosis (BV) in particular formulations. It can appear as a 2% cream, a 2% vaginal gel or a 100 mg vaginal suppository known as an ovule. These products differ in dose delivery, number of applications, packaging and important precautions, even though they share clindamycin as the active antibacterial ingredient.
The CDC lists 2% intravaginal clindamycin cream among recommended BV treatments, with certain oral and ovule formulations among alternative regimens and additional single-dose branded presentations discussed separately. That does not mean a patient should select products interchangeably. The clinical decision requires a diagnosis, pregnancy and allergy considerations, and a review of product-specific instructions. See clindamycin for BV for the indication-focused discussion.
This page is a front-door product guide for identifying which vaginal form was actually prescribed. It focuses on the distinctions between cream, gel and ovules, including pharmacy verification and warnings affecting barrier contraception. It is not a self-treatment plan or a claim that every branded product is currently stocked.
Vaginal clindamycin is not a single generic presentation. Some creams are supplied for an extended labeled course with disposable applicators; the Clindesse branded cream is a single-dose prefilled applicator. Xaciato is a 2% vaginal gel supplied with a user-filled applicator. Cleocin Vaginal Ovules are 100 mg suppositories.
A pharmacy listing should therefore communicate more than the word “vaginal.” Match exact form, concentration or unit strength, packaging, named product if specified, and the prescription instructions. None of these forms should be replaced by clindamycin topical acne gel.
| Form | Product identity | Distinctive verification |
|---|---|---|
| Standard 2% cream | Cream with applicator course | Tube and number of applicators |
| Single-dose 2% cream | Clindesse-type presentation | Prefilled one-time applicator |
| 2% vaginal gel | Xaciato product family | Gel tube and user-filled applicator |
| 100 mg ovules | Cleocin Vaginal Ovules | Suppository units and package |
| Topical acne gel | Not a vaginal formulation | Do not substitute across routes |
Clindamycin 2% vaginal cream is a familiar intravaginal BV treatment. The CDC discusses a standard regimen for this cream, but the correct course for an individual patient is determined by the prescription and product label. A tube with multiple disposable applicators should not be confused with a single prefilled applicator.
Cream may contain oil-based components that weaken latex barrier products. Product labeling and CDC guidance identify a period after use when latex condoms or diaphragms may be less reliable. The cream product guide focuses on formulation and applicator differences.
Clindesse is a single-dose 2% vaginal cream in a prefilled applicator. Xaciato is a separate single-dose 2% vaginal gel delivered from its tube through a user-filled applicator. The identical percentage and general concept of a single application do not establish equivalence.
This distinction matters when patients search for a single-dose product or ask a pharmacist to substitute one form for another. Read about Clindesse and Xaciato as individual product entities, and use single-dose vaginal clindamycin for the cross-product concept.
A vaginal ovule is a suppository, not a gel-filled applicator. Cleocin Vaginal Ovules contain clindamycin in a 100 mg unit for intravaginal use. The number of units in a prescribed course and the package structure differ from vaginal cream and gel.
The ovule base can weaken latex or rubber barrier products, with a label-specific restriction after treatment. Those warnings should not be silently replaced by the interval for creams or Xaciato. The dedicated ovules guide explains this dosage form in detail.
Standard clindamycin vaginal cream is oil-based and CDC guidance cautions that it may weaken latex condoms and diaphragms for several days after treatment. Ovules use an oily base with a different post-treatment interval. The Xaciato label instead has a specific warning that polyurethane condoms may be weakened for seven days after the single treatment.
These details cannot be safely summarized as “all clindamycin vaginal forms damage condoms in the same way.” Patients using barrier contraception should read the actual dispensed label and ask a clinician or pharmacist how to maintain reliable protection during the relevant interval.
Barrier warnings do not replace formal contraindication screening. Conventional CLEOCIN vaginal cream and CLEOCIN vaginal ovules labels contraindicate use with certain prior bowel diseases or antibiotic-associated colitis, along with specified hypersensitivity histories. The XACIATO vaginal gel label, by contrast, lists hypersensitivity to clindamycin or lincomycin as its formal contraindication and separately warns about C. difficile-associated diarrhea. These differences should be attributed to the precise product, not generalized across all vaginal clindamycin.
BV results from a change in vaginal bacterial balance, but discharge or odor can also arise from conditions needing a different test or treatment. A clinician may review symptoms, examination findings and tests, especially with recurring symptoms, pregnancy or concerns about sexually transmitted infections.
A vaginal clindamycin prescription should follow an appropriate clinical assessment rather than being selected from a web catalog for any genital symptom. The clinical BV overview covers diagnosis and follow-up separately from this product-family guide.
Oral clindamycin capsules have different dosing and systemic-risk considerations from vaginal treatments. The CDC lists oral clindamycin as an alternative BV regimen in particular circumstances, but that does not mean a patient should replace prescribed vaginal medicine with leftover oral capsules.
Only the prescriber can decide whether a different route or antibiotic is suitable for a specific presentation. The oral clindamycin guide addresses the systemic product family without turning this page into an unsupervised route-comparison tool.
A catalog may group these medicines under a single ingredient name while presenting different units and packages. Ask the dispensing pharmacist to repeat the full name, strength, form, applicator format and any requested brand. Confirm that the pharmacy is able to dispense the actual written prescription.
If the item is not available, it is safer to contact the prescriber than to order a similarly named product independently. An old label or drug-reference entry does not prove live stock, and online listings can be out of date.
BV symptoms may persist or recur. Repeatedly purchasing a previously prescribed product is not a substitute for determining whether the same diagnosis still applies. A clinician can reconsider testing, a different cause of symptoms, pregnancy context or other available treatments.
Fever, pelvic pain, new unusual bleeding, pregnancy concerns or symptoms suggesting another infection call for timely medical evaluation. Vaginal clindamycin is a prescription product for a defined indication, not an all-purpose vaginal cleanser or preventive wash.
prescription vaginal clindamycin is a prescription vaginal product, not an over-the-counter skin treatment. A pharmacy needs to match the name or authorized generic, exact vaginal form, concentration, applicator configuration and prescriber instructions. The distinction between a cream, gel and ovule is clinically meaningful even when the product name contains clindamycin. See U.S. prescription requirements for the legal access framework.
Ask which product family has been prescribed: multidose 2% cream, single-dose cream, Xaciato gel or 100 mg ovules. The packages and instructions are not interchangeable. If a pharmacy proposes a different formulation, ask the dispensing pharmacist to contact the prescriber when needed. Consumers should not translate the percentage on one package into an unsupervised dose of another form. The availability verification guide explains how to inquire about a precise product without assuming any pharmacy has current stock.
Product-specific warnings are especially important for barrier contraception: oil-based creams can weaken latex barriers, ovules have a separate post-treatment restriction, and Xaciato has a specific polyurethane-condom warning. The correct interval depends on the exact product. Patients should follow the particular package instructions for intercourse, other vaginal products and barrier contraception. These restrictions differ among cream, gel and ovule formulations; advice borrowed from a different clindamycin product can be wrong.
With prescription vaginal clindamycin, local administration does not eliminate the risk of antibiotic-associated diarrhea, including potentially serious C. difficile-associated illness. Severe or persistent diarrhea, bloody stools, marked abdominal pain or serious allergic symptoms warrant prompt clinical assessment. New fever, pelvic pain, bleeding or symptoms that do not fit a previously confirmed diagnosis should be assessed rather than repeatedly self-treated.
Vaginal cream tubes, single-dose prefilled cream applicators, a vaginal gel kit and ovule packages represent different products and can have markedly different coverage rules. Payment varies with the precise brand or generic, applicator package, available supply, formulary coverage and whether the pharmacy can dispense the prescribed presentation. Product cost should never be estimated from a similarly named skin gel or oral capsule; the label and route must match.
Before accepting prescription vaginal clindamycin, confirm the vaginal route, concentration, form, number of applicators or units, expiration, storage instructions and any contraceptive-barrier warning. For ways to evaluate payment without unreliable live price quotes, use vaginal clindamycin cost factors.
U.S. products include 2% vaginal cream, certain 2% gel presentations and 100 mg vaginal ovules. They have different labels and package instructions.
No. The dosage forms and product-specific packaging, administration instructions and precautions differ.
No. Xaciato is a 2% prescription vaginal gel supplied with a user-filled single-dose applicator.
Clindesse is a prescription single-dose 2% vaginal cream with a prefilled applicator, distinct from standard multidose cream.
No. Ovules are vaginal suppositories; oral capsules are taken by mouth and are not interchangeable.
Some products have specific warnings. Cream and ovules can affect latex or rubber barriers, while Xaciato warns about polyurethane condoms. Check the exact label.
No. Topical acne gel is not a vaginal product and must not be substituted.
No. The clindamycin vaginal products discussed are prescription medications in the United States.
Provide the exact prescribed form, strength or unit, brand if specified and applicator details; ask about label warnings and availability.